Lin Shumeng, Yuan Liuliu, Chen Xiao, Chen Shiyin, Wei Mengling, Hao Bingjie, Zheng Tiansheng, Fan Lihong
Institute of Energy Metabolism and Health, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Cancer Biol Med. 2025 Jun 19;22(6):648-71. doi: 10.20892/j.issn.2095-3941.2024.0596.
Lung cancer is the leading cause of cancer-related deaths worldwide. Chemotherapy is associated with side effects, such as damage to myeloid cells and a reduction in the number of immune cells in patients. In addition, tumor cells hijack the mitochondria of immune cells through tunnel nanotubes, thereby weakening immune ability.
In this study the effects of direct mitochondria transplantation on cancer cell proliferation and chemotherapeutic sensitivity were determined, as well as anti-tumor immunity in and lung cancer models.
A combination of mitochondrial transplantation and cisplatin chemotherapy was shown for the first time to significantly improve immune infiltration of advanced non-small cell lung cancer (NSCLC) and overcome the shortcomings of cisplatin chemotherapy, including damage to myeloid cells and a reduction in the number of immune cells.
The findings of the current study provide valuable recommendations for enhancing immune infiltration and augmenting anti-tumor efficacy during chemotherapy in advanced NSCLC. In addition, the findings support "mitochondrial transfer" as a novel paradigm in tumor treatment.
肺癌是全球癌症相关死亡的主要原因。化疗会产生副作用，如对骨髓细胞的损伤以及患者体内免疫细胞数量的减少。此外，肿瘤细胞通过隧道纳米管劫持免疫细胞的线粒体，从而削弱免疫能力。
在本研究中，测定了直接线粒体移植对癌细胞增殖和化疗敏感性的影响，以及在肺癌模型中的抗肿瘤免疫作用。
首次表明线粒体移植与顺铂化疗联合使用可显著改善晚期非小细胞肺癌（NSCLC）的免疫浸润，并克服顺铂化疗的缺点，包括对骨髓细胞的损伤和免疫细胞数量的减少。
本研究结果为增强晚期NSCLC化疗期间的免疫浸润和提高抗肿瘤疗效提供了有价值的建议。此外，这些结果支持“线粒体转移”作为肿瘤治疗的一种新范式。
Zotero 插件
